OCT 06, 2016 6:00 AM PDT

Detection and analysis of circulating tumor cells - challenges and solutions

  • Director, Liquid Biopsy and Site Manager, QIAGEN Hannover Germany
      Dr. Siegfried Hauch studied biology at the Albert Einstein University in Ulm and received his PhD 1997 in plant physiology and molecular biology at the Eberhard Karls University Tübingen. Until 2001 he was Product Manager for imaging systems and microarray technologies at Biozym Diagnostics GmbH and changed therafter to AdnaGen AG as Marketing Manager in 2001. In addition to his marketing responsibilities he was director of R&D since 2006 to build, secure and enhance the AdnaGen circulating tumor cell business and, after the accquistion by Alere Inc. in 2010, he was holding the position as CSO and General Manager at Alere/AdnaGen GmbH. Since 2015 Dr. Hauch serves as Director of Liquid Biopsy and Site Manager at QIAGEN Hannover GmbH.


    Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and profiling CTCs from blood samples is very challenging. In this webinar, we will introduce the AdnaTests, which uses the Combination of Combinations Principle (COCP) to enable enriching and detecting CTCs in whole blood with high specificity and sensitivity, and how to overcome challenges in CTC enrichment and detection. The AdnaTests combine an immunomagnetic capturing method that increases purity, and is followed by molecular profiling of the captured CTCs. In addition, leukocyte contamination is another issue in CTCs detection and may lead to false positive results due to illegitimate expression of target genes or false interpretation. The AdnaWash allows to reduce leukocyte contamination to such a level that whole gene panels can be analyzed while maintaining the required specificity and sensitivity. Join us and learn more about this well-known technology and applications.

    Show Resources
    Show Resources